Asia-Pacific Tumor Markers Testing Market, 2019-2023: A 17-Country Analysis--Supplier Shares and Strategies, Volume and Sales Segment Forecasts, Emerging Tests, Technologies and Opportunities

This new 17-country report is available by country, market segment, section, or individual test.

This report is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic testing market, in evaluating emerging opportunities and developing effective business strategies during the next five years.

The report provides granular market segmentation analysis and forecasts for over 40 tumor markers; profiles leading suppliers and recent market entrants with innovative technologies and products; reviews current and emerging assays; reviews current instrumentation; evaluates emerging technologies; and offers specific opportunities and growth strategies for suppliers.

Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.

Country Analyses

Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Myanmar, New Zealand, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam

Business Opportunities and Strategic Recommendations

- Specific new product development opportunities with potentially significant market appeal during the next five years.

- Design criteria for new products.

- Alternative market penetration strategies.

- Potential market entry barriers and risks.

Over 200 Current and Emerging Cancer Diagnostic Tests

- Oncogenes - Biochemical Markers - Growth Factors - Colony Stimulating Factors - Hormones - Immunohistochemical Stains - Lymphokines

- ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.

Supplier Shares, Sales and Volume Forecasts

- Sales and market shares of major cancer diagnostic product suppliers in major countries by individual test.

- Five-year test volume and sales forecasts for major cancer diagnostic assays.

Instrumentation Review

- Analysis of major molecular diagnostic and immunodiagnostic analyzers used for cancer testing, including their operating characteristics, features and selling prices.

Technology Assessment

- Assessment of latest technologies and their potential applications for cancer diagnostic testing.

- Review of competing/complementing technologies.

- Companies, universities and research centers developing new cancer diagnostic tests and detection technologies.

Competitive Strategies

- Strategic assessments of major suppliers and start-up firms developing innovative cancer diagnostic technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.

- The companies analyzed in the report include:

- Abbott
- Agilent Technologies
- Applied Gene Technologies
- Arca Biopharma
- Beckman Coulter/Danaher
- Becton Dickinson
- bioMerieux
- Bio-Rad
- CellSearch
- Cepheid
- Clinical Genomics
- Decode Genetics
- DiaSorin
- Diazyme
- Eiken Chemical
- Elitech Group
- Enzo Biochem
- Epigenomics
- Exact Sciences
- Fujirebio
- Guided Therapeutics
- Hologic
- Janssen Diagnostics
- Leica Biosystems
- Kyowa Medex
- Myriad Genetics
- OncoLab
- Ortho-Clinical Diagnostics
- Panacea Pharmaceuticals
- PerkinElmer
- Polymedco
- Qiagen
- Quest Diagnostics
- Roche
- Scienion
- Sequenom
- Siemens Healthineers
- Takara Bio
- Theradiag
- Thermo Fisher
- Tosoh
- Vermillion
- Wako Pure Chemicals


I. Introduction
II. Market Overview
III. Major Product Development Opportunities
A. Reagent Kits and Test Systems/Panels
B. Instrumentation
C. Computers, Software and Automation
D. Auxiliary Products
IV. Design Criteria for Decentralized Testing Products
V. Alternative Market Penetration Strategies
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies
VI. Potential Market Entry Barriers and Risks
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
VII. Market and Technology Overview
A. Cancer Statistics and Etiology
1. Breast Cancer
2. Lung Cancer
3. Colon and Rectum Cancer
4. Prostate Cancer
5. Stomach Cancer
6. Leukemia
7. Lymphoma
8. Oral Cancer
9. Skin Cancer
10. Uterine Cancer
11. Ovarian Cancer
12. Bladder Cancer

B. Major Current and Emerging Cancer Diagnostic Tests
1. Introduction
2. Tumor Marker Classification
3. ACTH
4. Alpha-Fetoprotein (AFP)
5. Beta-2 Microglobulin
6. CA 15-3/27.29
7. CA 19-9
8. CA-125
9. Calcitonin
10. Carcinoembrionic Antigen (CEA)
11. Estrogen and Progesterone Receptors
12. Ferritin
13. Gastrin
14. Human Chorionic Gonadotropin (HCG)
15. Insulin
16. NSE
17. Occult Blood
18. PAP Smear/HPV
19. Prostatic Acid Phosphatase (PAP)
20. Prostate-Specific Antigen (PSA)
21. Squamous Cell Carcinoma Antigen (SCC)
22. T and B Lymphocytes
23. TdT
24. Thyroglobulin
25. Tissue Polypeptide Antigen (TPA)
26. Biochemical Tumor Markers
27. Oncogenes
- Abl/abl-bcr
- AIB1
- BCL-2
- BRCA1
- CD44
- C-fos
- C-myb
- C-myc
- CYP-17
- Erb-B
- HPC1
- N-myc
- P40
- P51
- P53
- PIK3CA
- PTI-1
- Ras
- Reg

- Sis
- Src
28. Polypeptide Growth Factors
- Basic Fibroblast Growth Factor
- Beta-TGF
- Cachectin (TNT)
- Calmodulin
- ECFR
- Nerve Growth Factor (NGF)
- Epidermal Growth Factor (EGF)
- Ornithine Decarboxylase
- Transferrin
- Transforming Growth Factor-Alpha
29. Ectopic Hormones
30. Colony Stimulating Factors
31. Lymphokines
- Alpha-Interferon
- B Cell Growth Factors
- B Cell Growth Factor (BCGF)
- Gamma-Interferon
- Interleukin-1 (IL-1)
- Macrophage Activating Factor
32. Immunohistochemical Stains
33. Emerging Tumor Markers
- N-Acetylglucosamine
- Actin
- Alpha-Actin
- Antineuronal Antibodies
- 7B2
- B72.3
- Bax
- BCD-F9
- BLCA-4
- Blood Group Antigens A,B,H
- CA 50
- CA 72-4/TAG-72
- CA 195
- CA-242
- CA-549
- CAM 26
- CAR-3
- Cathepsin-D
- Chromogranin A and B
- Cluster 1 Antigen
- Cluster-5/5A Antigen
- CTA
- CU18
- DR-70

- DU-PAN-2
- Endometrial Bleeding Associated Factor
- Endostatin
- Epithelial Membrane Antigen
- Feulgen Hydrolysis
- Fibronectin
- FSH
- (1->3)-L-fucosyltransferase
- Gastrin-Releasing Peptide (GRP)
- GDCFP-15
- Glucagon
- Glycoamines
- H23
- Her-2
- Human Carcinoma Antigen
- HPA
- HSP27
- Intermediate Filaments
- Cytokeratins/CK18/Cyfra 21-1
- Desmin
- Gliofibrillary Acid Protein
- Neurofilaments
- Vimentin
- KA 93
- Kinases
- KP16D3
- LAI
- Leukocyte Common Antigen
- Lewis Antigens
- Lysophosphatidic Acid (LPA)
- Ma 695/Ma 552
- MABDF3
- MAG
- ME1
- Minactivin
- MN/CA9
- MSA
- Mucin Cancer Antigen (MCA)
- Multiple Tumor Suppressor 1
- Myosin
- NEA-130
- NMP22
- OA-519
- Opioid Peptides
- P-glycoprotein
- Pancreatic Oncofetal Antigen (POA)
- Placental Lactogen
- PR92

- Proliferative Index, Ki-67
- Px
- RB Inactivation/Deletion
- Ret
- SCCL 175
- Selectin
- Sialic Acid
- Sialyl SSEA-1/SLX
- SN10
- Somatostatin
- TA-90
- TABA
- Tachykinin
- TAG 12
- TPS
- Troponin
- Tubulin
- VCAM
- VEGF
- Villen
C. Cancer Diagnostic Testing Instrumentation Review and Market Needs
D. Current and Emerging Cancer Diagnostic Technologies
1. Monoclonal and Polyclonal Antibodies
2. Immunoassays
3. Molecular Diagnostics
4. Chromosome Analysis
a. Chronic Myelogenous Leukemia (CML)
b. Acute Myeloid Leukemia (AML)
c. Acute Lymphoblastic Leukemia (ALL)
d. Malignant Lymphomas Lymphoid Malignancies
e. Chronic Lymphocytic Leukemia (CLL)
f. Solid Cancers
g. Chromosomal Translocation and Oncogenes
5. Artificial Intelligence
6. Flow Cytometry
7. Two Dimensional Gel Electrophoresis (2-DGE)
8. Biosensors
9. Competing/Complementing Technologies
E. Personal Testing

VIII. Country Market Analyses: Test Volume and Sales Forecasts, Supplier Shares
- Australia
- Bangladesh
- China
- Hong Kong
- India
- Indonesia
- Japan
- Malaysia
- Myanmar
- New Zealand
- Pakistan
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
IX. Competitive Profiles
- Abbott
- AdnaGen/Alere
- Agilent Technologies
- Applied Gene Technologies
- Arca Biopharma
- Beckman Coulter/Danaher
- Becton Dickinson
- Biomedical Diagnostics
- bioMerieux
- Bio-Rad
- CellSearch
- Cepheid
- Correlogic Systems/Vermillion
- Decode Genetics
- Diadexus
- Diagnocure
- Diasorin
- Eiken Chemical
- Elitech Group
- Enterix
- Enzo Biochem
- Epigenomics
- Exact Sciences
- Fujirebio
- Guided Therapeutics
- Hologic/Gen-Probe

- Kreatech/Leica
- Kyowa Medex
- Mackay Life Sciences
- Myriad Genetics
- OncoLab
- Ortho-Clinical Diagnostics
- Panacea Pharmaceuticals
- Polartechnics
- Polymedco
- PreMD
- Qiagen
- Quest Diagnostics
- Radient Pharmaceuticals
- Roche
- Scienion
- Sequenom
- Siemens Healthcare
- Takara Bio
- Targeted Diagnostics & Therapeutics
- Tosoh
- Thermo
- Veridex
- Wako Pure Chemicals
- Wallac/PE
- Zila
X. Appendix: Major Universities and Research
Centers Developing Cancer Diagnostic
Technologies and Applications

List Of Tables


Australia Cancer Diagnostic Volume Forecasts by Test
Australia Cancer Diagnostics Sales Forecasts by Test
Bangladesh Cancer Diagnostic Volume Forecasts by Test
Bangladesh Cancer Diagnostics Sales Forecasts by Test
China Cancer Diagnostic Volume Forecasts by Test
China Cancer Diagnostics Sales Forecasts by Test
Hong Kong Cancer Diagnostic Volume Forecasts by Test
Hong Kong Cancer Diagnostics Sales Forecasts by Test
India Cancer Diagnostic Volume Forecasts by Test
India Cancer Diagnostics Sales Forecasts by Test
Indonesia Cancer Diagnostic Volume Forecasts by Test
Indonesia Cancer Diagnostics Sales Forecasts by Test
Japan Executive Summary Table: Total Tumor
Marker Test Volume and Sales Forecast by Market Segment
Japan, Estimated Cancer Death Rates
Per 100,000 Population
Japan, Laboratories Performing Tumor
Marker Tests by Market Segment
Japan, Hospital Laboratories Performing
Tumor Marker Tests by Bed Size
Japan, Commercial/Private Laboratories
Performing Tumor Marker Tests
by Annual Test Volume
Japan, Total Tumor Marker Testing Volume
Forecast by Market Segment
Japan, All Market Segments Major Tumor
Marker Test Volume Forecast
Japan, Hospital Laboratories Major Tumor
Marker Test Volume Forecast by Test

Japan, Commercial/Private Laboratories Major
Tumor Marker Test Volume Forecast
Japan, Total Tumor Marker Sales
Forecast by Market Segment
Japan, All Market Segments Major Tumor
Marker Sales Forecast by Test
Japan, Hospital Laboratories Major Tumor
Marker Sales Forecast by Test
Japan, Commercial/Private Laboratories Major
Tumor Marker Sales Forecast by Test
Japan, ACTH Test Volume and Diagnostics Sales
Forecast by Market Segment
Japan, AFP Test Volume and Diagnostics Sales
Forecast by Market Segment
Japan, Beta-2 Microglobulin Test Volume and
Diagnostics Sales Forecast by Market Segment
Japan, CA 15-3/27.29 Test Volume and
Diagnostics Sales Forecast by Market Segment
Japan, CA 19-9 Test Volume and Diagnostics
Sales Forecast by Market Segment
Japan, CA-125 Test Volume and Diagnostics
Sales Forecast by Market Segment
Japan, Calcitonin Test Volume and Diagnostics
Sales Forecast by Market Segment
Japan, Cathepsin Test Volume and Diagnostics
Sales Forecast by Market Segment
Japan, CEA Test Volume and Diagnostics
Sales Forecast by Market Segment
Japan, Chromogranin Test Volume and
Diagnostics Sales Forecast by Market Segment
Japan, Colon-Specific Antigen Test Volume
and Diagnostics Sales Forecast by Market Segment

Japan, Cytokeratins Test Volume and
Diagnostics Sales Forecast by Market Segment
Japan, Estrogen Receptor Test Volume and
Diagnostics Sales Forecast by Market Segment
Japan, Ferritin Test Volume and
Diagnostics Sales Forecast by Market Segment
Japan, Gastrin Test Volume and
Diagnostics Sales Forecast by Market Segment
Japan, HCG Test Volume and Diagnostics Sales
Forecast by Market Segment
Japan, Insulin Test Volume and Diagnostics
Sales Forecast by Market Segment
Japan, Interferons Test Volume and
Diagnostics Sales Forecast by Market Segment
Japan, Interleukins Test Volume and
Diagnostics Sales Forecast by Market Segment
Japan, Lymphocyte Subtyping Test Volume and
Diagnostics Sales Forecast by Market Segment
Japan, NSE Test Volume and Diagnostics Sales
Forecast by Market Segment
Japan, Nucleolar Test Volume and
Diagnostics Sales Forecast by Market Segment
Japan, Occult Blood Test Volume and
Diagnostics Sales Forecast by Market Segment
Japan, Oncogenes Test Volume and
Diagnostics Sales Forecast by Market Segment
Japan, Pancreatic Oncofetal Antigen
Test Volume and Diagnostics
Japan, PAP Smear Test Volume and
Diagnostics Sales Forecast by Market Segment
Japan, Parathyroid Hormone
Test Volume and Diagnostics
Sales Forecast by Market Segment

Japan, Progesterone Receptor
Test Volume and Diagnostics
Sales Forecast by Market Segment
Japan, PAP Test Volume and Diagnostics Sales
Forecast by Market Segment
Japan, PSA Test Volume and Diagnostics Sales
Forecast by Market Segment
Japan, S-100 Protein Test Volume and
Diagnostics Sales Forecast by Market Segment
Japan, Serotonin Test Volume and
Diagnostics Sales Forecast by Market Segment
Japan, Sialic Acid Test Volume and
Diagnostics Sales Forecast by Market Segment
Japan, Squamous Cell Carcinoma Antigen
Test Volume and Diagnostics Sales
Forecast by Market Segment
Japan, TDT Test Volume and Diagnostics
Sales Forecast by Market Segment
Japan, Thymidine Kinase
Test Volume and Diagnostics
Sales Forecast by Market Segment
Japan, Thyroglobulin
Test Volume and Diagnostics
Sales Forecast by Market Segment
Japan, TPA, Test Volume and Diagnostics
Sales Forecast by Market Segment
Japan, Total Tumor Marker
Sales by Major Suppliers
Japan, AFP Testing Market Diagnostics
Sales by Major Supplier
Japan, CA 15-3/27.29 Testing Market
Diagnostics Sales by Major Supplier
Japan, CA 19-9 Testing Market Diagnostics
Sales by Major Supplier

Japan, CA 125 Testing Market Diagnostics
Sales by Major Supplier
Japan, Calcitonin Testing Market Diagnostics
Sales by Major Supplier
Japan, PAP Testing Market Diagnostics
Sales by Major Supplier
Japan, PSA Testing Market Diagnostics
Sales by Major Supplier
Malaysia Cancer Diagnostic Volume Forecasts by Test
Malaysia Cancer Diagnostics Sales Forecasts by Test
Myanmar Cancer Diagnostic Volume Forecasts by Test
Myanmar Cancer Diagnostics Sales Forecasts by Test
New Zealand Cancer Diagnostic Volume Forecasts by Test
New Zealand Cancer Diagnostics Sales Forecasts by Test
Pakistan Cancer Diagnostic Volume Forecasts by Test
Pakistan Cancer Diagnostics Sales Forecasts by Test
Philippines Cancer Diagnostic Volume Forecasts by Test
Philippines Cancer Diagnostic Volume Forecasts by Test
Singapore Cancer Diagnostic Volume Forecasts by Test
Singapore Cancer Diagnostics Sales Forecasts by Test
South Korea Cancer Diagnostic Volume Forecasts by Test
South Korea Cancer Diagnostics Sales Forecasts by Test
Taiwan Cancer Diagnostic Volume Forecasts by Test
Taiwan Cancer Diagnostics Sales Forecasts by Test
Thailand Cancer Diagnostic Volume Forecasts by Test
Thailand Cancer Diagnostics Sales Forecasts by Test

Vietnam Cancer Diagnostic Volume Forecasts by Test
Vietnam Cancer Diagnostics Sales Forecasts by Test
Tumor Marker Classification
Major Companies Developing or
Marketing ACTH Tests
Major Companies Developing or
Marketing AFP Tests
Major Companies Developing or
Marketing Beta-2 Microglobulin Tests
Major Companies Developing or
Marketing CA 15-3/27.29 Tests
Major Companies Developing or
Marketing CA 19-9 Tests
Major Companies Developing or
Marketing CA 125 Tests
Major Companies Developing or
Marketing Calcitonin Tests
Major Companies Developing or
Marketing CEA Tests
Major Companies Developing or
Marketing Estrogen Receptor Tests
Major Companies Developing or
Marketing Progesterone Receptor Tests
Major Companies Developing or
Marketing Ferritin Tests
Major Companies Developing or
Marketing Gastrin Tests
Major Companies Developing or
Marketing HCG Tests
Major Companies Developing or
Marketing Insulin Tests

Major Companies Developing or
Marketing NSE Tests
Major Companies Developing or
Marketing Occult Blood Tests
Major Companies Developing or
Marketing PAP Smear/HPV Tests
Major Companies Developing or
Marketing PAP Tests
Major Companies Developing or
Marketing PSA Tests
Major Companies Developing or Marketing
Lymphocyte Subclassification Tests
Biochemical Markers Potential Applications
In Cancer Diagnosis
Oncogenes Potential Applications
In Cancer Diagnosis
Major Companies Developing or
Marketing Oncogene Tests
Growth Factors Potential Applications
In Cancer Diagnosis
Colony Stimulating Factors Potential
Applications in Cancer Diagnosis
Lymphokines Potential Applications
in Cancer Diagnosis
Immunohistochemical Stains Potential
Applications in Cancer Diagnosis

2020 Asia-Pacific Transfusion Diagnostics Market for 40 Immunohematology and NAT Assays: A 17-Country Analysis--Supplier Shares and Strategies, Volume and Sales Segment Forecasts, Emerging Technologies,Instrumentation and Opportunities

This new 17-country report is available by country, market segment, section, or individual test. The report is designed to help current suppliers and potential market entrants identify and evaluate

USD 9500 View Report

Asia-Pacific Tumor Markers Sales Segment Forecasts for over 40 Tests: A 17-Country Analysis--Supplier Shares and Strategies, Volume and Sales Segment Forecasts, Emerging Tests, Technologies and Opportunities

This new 17-country report is available by country, market segment, section, or individual test. This report is designed to assist diagnostics industry executives, as well as companies planning to

USD 14500 View Report

2020 Immunodiagnostics Market: US, Europe, Japan--Spot Fast-Growing Market Segments--Supplier Shares and Segment Forecasts for over 100 Therapeutic Drug Monitoring, Endocrine Function, Tumor Markers, Special Chemistry, Immunoproteins, and Drugs of Abuse Tests

This comprehensive seven-country report contains 1,115 pages and 450 tables. The report explores future trends in the U.S., five major European countries (France, Germany, Italy, Spain, UK) and Japan; provides

USD 24500 View Report

2020 Tumor Markers: Unlocking Mystery of Cancer--US, Europe, Japan--Suppliers Shares and Market Segment Forecasts by Tumor Marker and Country, Competitive Analysis, Technological Breakthroughs, Emerging Tests

This new report is a study of the major business opportunities emerging in the global cancer diagnostics market during the next five years. The report examines trends in the U.S.,

USD 24500 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available